## Anthony J Demetris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6980393/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study. Transplantation, 2022, 106, 806-820.	1.0	7
2	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. Transplantation, 2022, 106, 562-574.	1.0	7
3	Clinicopathological Analysis of Uterine Allografts Including Proposed Scoring of Ischemia Reperfusion Injury and T-cell–mediated Rejection—Dallas UtErus Transplant Study: A Pilot Study. Transplantation, 2022, 106, 167-177.	1.0	10
4	A retrievable, dual-chamber stent protects against warm ischemia of donor organs in a model of donation after circulatory death. Surgery, 2022, 171, 1100-1107.	1.9	3
5	Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant. JAMA Surgery, 2022, 157, 189.	4.3	154
6	Graft Fibrosis Over 10 to 15 Years in Pediatric Liver Transplant Recipients: Multicenter Study of Paired, Longitudinal Surveillance Biopsies. Liver Transplantation, 2022, 28, 1051-1062.	2.4	8
7	Surveillance Biopsies in Pediatric Liver Transplantation: Is the Juice Worth the Squeeze?. Liver Transplantation, 2022, 28, 754-755.	2.4	1
8	Standardising the histological assessment of late postâ€ŧransplant biopsies from paediatric liver allograft recipients. Liver Transplantation, 2022, , .	2.4	3
9	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	4.7	28
10	Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. Hepatology, 2021, 73, 1985-2004.	7.3	57
11	An evaluation of the safety and preliminary efficacy of peri―and post―perative treprostinil in preventing ischemia and reperfusion injury in adult orthotopic liver transplant recipients. Clinical Transplantation, 2021, 35, e14298.	1.6	8
12	Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality. Transplantation Proceedings, 2021, 53, 1682-1689.	0.6	2
13	IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. American Journal of Transplantation, 2020, 20, 513-524.	4.7	22
14	Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. Hepatology, 2020, 72, 569-583.	7.3	45
15	Precision transplant pathology. Current Opinion in Organ Transplantation, 2020, 25, 412-419.	1.6	6
16	A three-tier Rescue stent improves outcomes over balloon occlusion in a porcine model of noncompressible hemorrhage. Journal of Trauma and Acute Care Surgery, 2020, 89, 320-328.	2.1	5
17	Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. American Journal of Transplantation, 2020, 20, 2173-2183.	4.7	30
18	Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. American Journal of Transplantation, 2020, 20, 2305-2317.	4.7	119

#	Article	IF	CITATIONS
19	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	4.7	437
20	Banff Digital Pathology Working Group: Going digital in transplant pathology. American Journal of Transplantation, 2020, 20, 2392-2399.	4.7	36
21	Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection. Journal of Clinical Investigation, 2020, 130, 5397-5412.	8.2	41
22	CD24hiCD38hi and CD24hiCD27+ Human Regulatory B Cells Display Common and Distinct Functional Characteristics. Journal of Immunology, 2019, 203, 2110-2120.	0.8	56
23	Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring. Transplantation, 2019, 103, 1306-1322.	1.0	21
24	Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. American Journal of Transplantation, 2019, 19, 1397-1409.	4.7	103
25	Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation. American Journal of Transplantation, 2018, 18, 2135-2147.	4.7	19
26	Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. Human Pathology, 2018, 73, 144-155.	2.0	16
27	Prospective Study of the Impact of Liver Biopsy Core Size on Specimen Adequacy and Procedural Complications. American Journal of Roentgenology, 2018, 210, 183-188.	2.2	29
28	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. Journal of Immunology, 2018, 200, 834-846.	0.8	23
29	Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. Gastroenterology, 2018, 155, 1838-1851.e7.	1.3	125
30	Fiveâ€year histological and serological followâ€up of operationally tolerant pediatric liver transplant recipients enrolled in WISPâ€R. Hepatology, 2017, 65, 647-660.	7.3	87
31	Chronic AMR in Liver Transplant. Transplantation, 2017, 101, 2062-2070.	1.0	19
32	NK1.1+ cells promote sustained tissue injury and inflammation after trauma with hemorrhagic shock. Journal of Leukocyte Biology, 2017, 102, 127-134.	3.3	9
33	Late graft dysfunction after pediatric heart transplantation is associated with fibrosis and microvasculopathy by automated, digital whole-slide analysis. Journal of Heart and Lung Transplantation, 2017, 36, 1336-1343.	0.6	15
34	Longterm outcome of the liver graft: The pathologist's perspective. Liver Transplantation, 2017, 23, S70-S75.	2.4	11
35	Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation, 2017, 101, 2399-2409.	1.0	42
36	A pilot study of operational tolerance with a regulatory Tâ€cellâ€based cell therapy in living donor liver transplantation. Hepatology, 2016, 64, 632-643.	7.3	333

#	Article	IF	CITATIONS
37	Prevention and treatment of liver allograft antibody-mediated rejection and the role of the â€~two-hit hypothesis'. Current Opinion in Organ Transplantation, 2016, 21, 209-218.	1.6	61
38	Dual chamber stent prevents organ malperfusion in a model of donation after cardiac death. Surgery, 2016, 160, 892-901.	1.9	4
39	ABO-compatible liver allograft antibody-mediated rejection. Current Opinion in Organ Transplantation, 2015, 20, 314-324.	1.6	48
40	IRF-1 Promotes Liver Transplant Ischemia/Reperfusion Injury via Hepatocyte IL-15/IL-15Rα Production. Journal of Immunology, 2015, 194, 6045-6056.	0.8	39
41	Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia. Journal of Hepatology, 2015, 63, 399-407.	3.7	11
42	Small proline rich protein 2a in benign and malignant liver disease. Hepatology, 2014, 59, 1130-1143.	7.3	20
43	SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clinical and Experimental Metastasis, 2013, 30, 877-890.	3.3	16
44	Roles of dendritic cells in murine hepatic warm and liver transplantation-induced cold ischemia/reperfusion injury. Hepatology, 2013, 57, 1585-1596.	7.3	43
45	Gut Bacteria Drive Kupffer Cell Expansion via MAMP-Mediated ICAM-1 Induction on Sinusoidal Endothelium and Influence Preservation-Reperfusion Injury after Orthotopic Liver Transplantation. American Journal of Pathology, 2013, 182, 180-191.	3.8	70
46	Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Current Opinion in Organ Transplantation, 2013, 18, 345-353.	1.6	32
47	A validated model for predicting outcome after liver transplantation: implications on transplanting the extremely sick. Transplant International, 2013, 26, 1108-1115.	1.6	13
48	Upper-Extremity Transplantation Using a Cell-Based Protocol to Minimize Immunosuppression. Annals of Surgery, 2013, 257, 345-351.	4.2	184
49	Preexisting epithelial diversity in normal human livers: A tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology, 2013, 57, 1632-1643.	7.3	39
50	PD-L1 and PD-L2 Protect The Heart In a T-Cell Receptor Transgenic Model Of Graft-Versus Host Disease. Blood, 2013, 122, 4479-4479.	1.4	0
51	Complete Immunosuppression Withdrawal and Subsequent Allograft Function Among Pediatric Recipients of Parental Living Donor Liver Transplants. JAMA - Journal of the American Medical Association, 2012, 307, 283-93.	7.4	324
52	Profound Depletion of Host Conventional Dendritic Cells, Plasmacytoid Dendritic Cells, and B Cells Does Not Prevent Graft-versus-Host Disease Induction. Journal of Immunology, 2012, 188, 3804-3811.	0.8	69
53	Long-Term Effects of Alemtuzumab on Regulatory and Memory T-Cell Subsets in Kidney Transplantation. Transplantation, 2012, 93, 813-821.	1.0	49
54	Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance. Liver Transplantation, 2012, 18, 1154-1170.	2.4	114

#	Article	IF	CITATIONS
55	Innate immunity alone is not sufficient for chronic rejection but predisposes healed allografts to T cell-mediated pathology. Transplant Immunology, 2012, 26, 113-118.	1.2	13
56	The Role of the A2a Receptor Agonist, Regadenoson, in Modulating Hepatic Artery Flow in the Porcine Small-for-Size Liver Graft. Journal of Surgical Research, 2012, 174, e37-e45.	1.6	6
57	Cooperation of p300 and PCAF in the Control of MicroRNA 200c/141 Transcription and Epithelial Characteristics. PLoS ONE, 2012, 7, e32449.	2.5	50
58	Experience with multimodality telepathology at the University of Pittsburgh Medical Center. Journal of Pathology Informatics, 2012, 3, 45.	1.7	97
59	Acute and Chronic Rejection in Upper Extremity Transplantation: What Have We Learned?. Hand Clinics, 2011, 27, 481-493.	1.0	26
60	Memory T Cells Migrate to and Reject Vascularized Cardiac Allografts Independent of the Chemokine Receptor CXCR3. Transplantation, 2011, 91, 827-832.	1.0	17
61	Langerhans cells are not required for graft-versus-host disease. Blood, 2011, 117, 697-707.	1.4	39
62	Memory T cells from minor histocompatibility antigen–vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood, 2011, 118, 5965-5976.	1.4	49
63	A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood, 2011, 118, 6209-6219.	1.4	39
64	Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4 <sup>+</sup> effector memory T cells. European Journal of Immunology, 2011, 41, 2782-2792.	2.9	16
65	Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology, 2011, 54, 216-228.	7.3	37
66	Graft-versus-Host Disease Is Independent of Innate Signaling Pathways Triggered by Pathogens in Host Hematopoietic Cells. Journal of Immunology, 2011, 186, 230-241.	0.8	62
67	Hereditary Hemorrhagic Telangiectasia of the Liver Complicated by Ischemic Bile Duct Necrosis and Sepsis: Case Report and Review of the Literature. Digestive Diseases and Sciences, 2010, 55, 2113-2117.	2.3	8
68	Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology, 2010, 51, 869-880.	7.3	44
69	Cytosolic phospholipase A2α and peroxisome proliferator-activated receptor γ signaling pathway counteracts transforming growth factor β-mediated inhibition of primary and transformed hepatocyte growth. Hepatology, 2010, 52, 644-655.	7.3	38
70	NK Cells Delay Allograft Rejection in Lymphopenic Hosts by Downregulating the Homeostatic Proliferation of CD8+ T Cells. Journal of Immunology, 2010, 184, 6649-6657.	0.8	57
71	Heterotopic Breast Epithelial Inclusion of the Heart: Report of a Case. American Journal of Surgical Pathology, 2010, 34, 1555-1559.	3.7	8
72	Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction. Biology of Blood and Marrow Transplantation, 2010, 16, 1222-1230.	2.0	24

#	Article	IF	CITATIONS
73	Evolution of hepatitis C virus in liver allografts. Liver Transplantation, 2009, 15, S35-S41.	2.4	70
74	Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transplant International, 2009, 22, 120-141.	1.6	57
75	Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transplant International, 2009, 22, 96-109.	1.6	101
76	Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests. Journal of Hepatology, 2009, 50, 501-510.	3.7	88
77	Histologic Graft Assessment After Clinical Islet Transplantation. Transplantation, 2009, 88, 1286-1293.	1.0	74
78	Donor APCs Promote Gvhd in MHC-Mismatched Transplants by Indirectly Presenting Host Minor Histocompatibility Antigens Blood, 2009, 114, 689-689.	1.4	1
79	Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Laboratory Investigation, 2008, 88, 865-872.	3.7	82
80	Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood, 2008, 111, 5242-5251.	1.4	75
81	Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial–mesenchymal transition (EMT) in cholangiocytes. Journal of Hepatology, 2008, 48, 276-288.	3.7	36
82	Cyclooxygenase-2–Derived Prostaglandin E2 Activates β-Catenin in Human Cholangiocarcinoma Cells: Evidence for Inhibition of These Signaling Pathways by ω3 Polyunsaturated Fatty Acids. Cancer Research, 2008, 68, 553-560.	0.9	101
83	Histologic Abnormalities are Common in Protocol Liver Allograft Biopsies From Patients With Normal Liver Function Tests. American Journal of Surgical Pathology, 2008, 32, 965-973.	3.7	71
84	Posttransplant Adenoviral Enteropathy in Patients With Small Bowel Transplantation. Archives of Pathology and Laboratory Medicine, 2008, 132, 703-705.	2.5	57
85	Growth Factor-Induced Mobilization of Dendritic Cells in Kidney and Liver of Rhesus Macaques: Implications for Transplantation. Transplantation, 2007, 83, 656-662.	1.0	18
86	Protection from acute cellular injury using Sleeping Beauty mediated telomerase gene transfer. Biochemical and Biophysical Research Communications, 2007, 363, 253-256.	2.1	4
87	Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. Hepatology, 2007, 45, 195-204.	7.3	131
88	Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. Hepatology, 2007, 46, 1946-1959.	7.3	51
89	Acute Antibody-mediated Rejection of Cardiac Transplants. Journal of Heart and Lung Transplantation, 2006, 25, 153-159.	0.6	274
90	CTLA4-Ig-Based Conditioning Regimen to Induce Tolerance to Cardiac Allografts. Journal of Surgical Research, 2006, 136, 238-246.	1.6	7

#	Article	IF	CITATIONS
91	Pathophysiologic Observations and Histopathologic Recognition of the Portal Hyperperfusion or Small-for-Size Syndrome. American Journal of Surgical Pathology, 2006, 30, 986-993.	3.7	223
92	Liver Transplantation in Precirrhotic Biliary Tract Disease: Portal Hypertension is Frequently Associated With Nodular Regenerative Hyperplasia and Obliterative Portal Venopathy. American Journal of Surgical Pathology, 2006, 30, 1454-1461.	3.7	65
93	The Difficulty of Eliminating Donor Leukocyte Microchimerism in Rat Recipients Bearing Established Organ Allografts. Transplantation, 2006, 81, 438-444.	1.0	8
94	A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nature Medicine, 2006, 12, 410-416.	30.7	889
95	3D-confocal structural analysis of bone marrow-derived renal tubular cells during renal ischemia/reperfusion injury. Laboratory Investigation, 2006, 86, 72-82.	3.7	10
96	Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology, 2006, 44, 489-501.	7.3	326
97	Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 2006, 44, 1012-1024.	7.3	319
98	COXâ€2â€ÐERIVED PGE2 ACTIVATES STAT3 THROUGH EP4â€MEDIATED PRODUCTION OF ILâ€6 AND EP1â€MEU ACTIVATION OF SRC IN HUMAN CHOLANGIOCARCINOMA CELLS. FASEB Journal, 2006, 20, A632.	DIATED	0
99	Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Laboratory Investigation, 2005, 85, 109-123.	3.7	45
100	Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. Journal of the American College of Surgeons, 2005, 200, 505-515.	0.5	167
101	An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology, 2005, 41, 1262-1271.	7.3	49
102	Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. Journal of Heart and Lung Transplantation, 2005, 24, 1710-1720.	0.6	1,538
103	Comparative analysis of the fate of donor dendritic cells and B cells and their influence on alloreactive T cell responses under tacrolimus immunosuppression. Clinical Immunology, 2005, 114, 199-209.	3.2	6
104	Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transplant Immunology, 2005, 14, 53-62.	1.2	95
105	Exogenous IL-6 Inhibits Acute Inflammatory Responses and Prevents Ischemia/Reperfusion Injury after Intestinal Transplantation. American Journal of Transplantation, 2004, 4, 482-494.	4.7	51
106	CASE REPORT: Acute Cholestatic Hepatitis Associated with Long-Term Use of Rofecoxib. Digestive Diseases and Sciences, 2004, 49, 459-461.	2.3	13
107	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 2004, 40, 667-676.	7.3	822
108	Regulation and Function of Trefoil Factor Family 3 Expression in the Biliary Tree. American Journal of Pathology, 2004, 165, 1907-1920.	3.8	43

#	Article	IF	CITATIONS
109	DE NOVO MALIGNANCIES AFTER INTESTINAL AND MULTIVISCERAL TRANSPLANTATION. Transplantation, 2004, 77, 1719-1725.	1.0	30
110	Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus. Transplantation, 2004, 78, 966-971.	1.0	158
111	Lessons of organ-induced tolerance learned from historical clinical experience1. Transplantation, 2004, 77, 926-929.	1.0	53
112	Suprahepatic Budd-Chiari syndrome treated with thrombectomy and cavoplasty. Digestive Diseases and Sciences, 2003, 48, 1637-1641.	2.3	5
113	Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology, 2003, 37, 871-879.	7.3	98
114	Chronic Rejection of Small Bowel Grafts: Pediatric and Adult Study of Risk Factors and Morphologic Progression. Pediatric and Developmental Pathology, 2003, 6, 240-250.	1.0	56
115	Antibody-Mediated Rejection Criteria - an Addition to the Banff '97 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	4.7	960
116	Minimal Evidence of Transdifferentiation from Recipient Bone Marrow to Parenchymal Cells in Regenerating and Long-Surviving Human Allografts. American Journal of Transplantation, 2003, 3, 1173-1181.	4.7	43
117	Tolerogenic immunosuppression for organ transplantation. Lancet, The, 2003, 361, 1502-1510.	13.7	478
118	Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Human Immunology, 2003, 64, 787-795.	2.4	18
119	Production of alpha 1,3-Galactosyltransferase-Deficient Pigs. Science, 2003, 299, 411-414.	12.6	1,003
120	PSEUDOTUMOR OF PANCREAS WITH BILIARY SCLEROSIS. American Journal of Gastroenterology, 2003, 98, S144-S145.	0.4	0
121	Kidney Transplantation Under a Tolerogenic Regimen of Recipient Pretreatment and Low-Dose Postoperative Immunosuppression With Subsequent Weaning. Annals of Surgery, 2003, 238, 520-525.	4.2	93
122	Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation, 2003, 76, 1487-1491.	1.0	64
123	Chimerism and tolerance in rat recipients of intestinal allografts from ALS-treated donors with and without adjunct naÃve–-donor-strain bone-marrow cells1. Transplantation, 2003, 75, 1575-1581.	1.0	10
124	Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis1. Transplantation, 2002, 73, 1598-1602.	1.0	51
125	Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells1. Transplantation, 2002, 74, 103-111.	1.0	18
126	Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. Journal of Hepatology, 2002, 37, 340-348.	3.7	38

#	Article	IF	CITATIONS
127	Five cases of fulminant hepatitis due to herpes simplex virus in adults. Digestive Diseases and Sciences, 2002, 47, 750-754.	2.3	69
128	Azithromycin-induced intrahepatic cholestasis. Digestive Diseases and Sciences, 2002, 47, 2186-2188.	2.3	55
129	ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology, 2002, 36, 439-450.	7.3	170
130	Replicative Senescence of Biliary Epithelial Cells Precedes Bile Duct Loss in Chronic Liver Allograft Rejection. American Journal of Pathology, 2001, 158, 1379-1390.	3.8	105
131	Clinical Intestinal Transplantation: A Decade of Experience at a Single Center. Annals of Surgery, 2001, 234, 404-417.	4.2	334
132	Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. Journal of Cancer Research and Clinical Oncology, 2001, 127, 187-192.	2.5	48
133	Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: Biologic and therapeutic implications. Hepatology, 2001, 34, 502-510.	7.3	57
134	LIVER TRANSPLANTATION FOR ALCOHOLIC CIRRHOSIS: LONG TERM FOLLOW-UP AND IMPACT OF DISEASE RECURRENCE1. Transplantation, 2001, 72, 619-626.	1.0	157
135	INTESTINAL TRANSPLANTATION AND BONE MARROW AUGMENTATION Transplantation, 2000, 69, S308-S309.	1.0	0
136	MIGRATION OF DONOR MHC CLASS II+ CELLS, ACTIVATION OF RECIPIENT IMMUNO RESPONSES, AND APOPTOSIS: COMPARISON BETWEEN HEART AND LIVER TRANSPLANTATION Transplantation, 2000, 69, S373.	1.0	0
137	Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center. Annals of Surgery, 2000, 232, 490-500.	4.2	484
138	IMMUNOMODULATION FOR INTESTINAL TRANSPLANTATION BY ALLOGRAFT IRRADIATION, ADJUNCT DONOR BONE MARROW INFUSION, OR BOTH1. Transplantation, 2000, 70, 1632-1641.	1.0	58
139	Spectrum of chronic hepatic allograft rejection and arteriopathy and the controversy of centrilobular necrosis. Liver Transplantation, 2000, 6, 102-103.	2.4	8
140	Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factorl²1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology, 2000, 32, 26-35.	7.3	121
141	Concanavalin A simultaneously primes liver hematopoietic and epithelial progenitor cells for parallel expansion during liver regeneration after partial hepatectomy in mice. Hepatology, 2000, 32, 256-267.	7.3	27
142	Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: With particular reference to chronic rejection. Liver Transplantation, 2000, 6, 686-702.	2.4	37
143	Nephropathy Due to Polyomavirus Type BK. New England Journal of Medicine, 2000, 342, 1361-1363.	27.0	201
144	The Mystique of Hepatic Tolerogenicity. Seminars in Liver Disease, 2000, 20, 497-510.	3.6	24

#	Article	IF	CITATIONS
145	THE EFFECT OF INTERLEUKIN-6 (IL-6)/gp130 SIGNALLING ON BILIARY EPITHELIAL CELL GROWTH, IN VITRO. Cytokine, 2000, 12, 727-730.	3.2	37
146	The Development and Compensation of Biliary Cirrhosis in Interleukin-6-Deficient Mice. American Journal of Pathology, 2000, 156, 1627-1639.	3.8	94
147	Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. Journal of Heart and Lung Transplantation, 2000, 19, 819-824.	0.6	125
148	BIOPSY OF MARGINAL DONOR KIDNEYS: CORRELATION OF HISTOLOGIC FINDINGS WITH GRAFT DYSFUNCTION1. Transplantation, 2000, 69, 1352-1357.	1.0	141
149	Biotin-related proteins of 70 and 72 kDa in gallbladder bile in primary biliary cirrhosis. Hepatology Research, 1999, 14, 154-160.	3.4	3
150	Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clinical Transplantation, 1999, 13, 39-44.	1.6	37
151	Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology, 1999, 29, 403-411.	7.3	245
152	CHIMERISM AND XENOTRANSPLANTATION. Surgical Clinics of North America, 1999, 79, 191-205.	1.5	12
153	AUTOIMMUNE LIVER DISEASES. Surgical Clinics of North America, 1999, 79, 147-152.	1.5	26
154	Dendritic cells/chimerism/alleviation of chronic allograft rejection. Journal of Leukocyte Biology, 1999, 66, 297-300.	3.3	7
155	Analysis of the Reversibility of Chronic Liver Allograft Rejection Implications for a Staging Schema*. American Journal of Surgical Pathology, 1999, 23, 1328.	3.7	63
156	HUMAN POLYOMA VIRUS-ASSOCIATED INTERSTITIAL NEPHRITIS IN THE ALLOGRAFT KIDNEY1. Transplantation, 1999, 67, 103-109.	1.0	465
157	EVIDENCE FOR HEAT SHOCK PROTEIN IMMUNITY IN A RAT CARDIAC ALLOGRAFT MODEL OF CHRONIC REJECTION1. Transplantation, 1999, 67, 156-164.	1.0	23
158	DONOR HEMATOPOIETIC PROGENITOR CELLS IN NONMYELOABLATED RAT RECIPIENTS OF ALLOGENEIC BONE MARROW AND LIVER GRAFTS1. Transplantation, 1999, 67, 833-840.	1.0	36
159	COSTIMULATORY MOLECULE EXPRESSION IN HEART ALLOGRAFTS DEVELOPING CHRONIC REJECTION AND TOLERANCE. Transplantation, 1999, 67, S18.	1.0	0
160	Transplantation tolerance, microchimerism, and the two-way paradigm. , 1998, 19, 441-455.		34
161	Role of splenectomy in human liver transplantation under modern-day immunosuppression. Digestive Diseases and Sciences, 1998, 43, 1931-1937.	2.3	46
162	Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type i ductular reaction in mice: Interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology, 1998, 28, 1260-1268.	7.3	96

#	Article	IF	CITATIONS
163	Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transplantation, 1998, 4, 448-454.	1.8	47
164	Heterogeneous Immediate Effects of Partial Left Ventriculectomy on Cardiac Performance. Circulation, 1998, 97, 839-842.	1.6	102
165	Chronic Liver Allograft Rejection. American Journal of Surgical Pathology, 1998, 22, 28-39.	3.7	62
166	LIVER TRANSPLANTATION WITH CAVOPORTAL HEMITRANSPOSITION IN THE PRESENCE OF DIFFUSE PORTAL VEIN THROMBOSIS. Transplantation, 1998, 65, 619-624.	1.0	169
167	LYMPHOID/NONLYMPHOID COMPARTMENTALIZATION OF DONOR LEUKOCYTE CHIMERISM IN RAT RECIPIENTS OF HEART ALLOGRAFTS, WITH OR WITHOUT ADJUNCT BONE MARROW1. Transplantation, 1998, 66, 350-357.	1.0	42
168	Chimerism after organ transplantation. Current Opinion in Nephrology and Hypertension, 1997, 6, 292-298.	2.0	22
169	The furture of transplantation: With particular reference to chimerism and xenotransplantation. Transplantation Proceedings, 1997, 29, 19-27.	0.6	31
170	Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers. Xenotransplantation, 1997, 4, 262-266.	2.8	4
171	Herpesvirus 6 Variant A Infection After Heart Transplantation with Giant Cell Transformation in Bile Ductular and Gastroduodenal Epithelium. American Journal of Surgical Pathology, 1997, 21, 847-853.	3.7	59
172	ATTENUATION OF LETHAL GRAFT-VERSUS-HOST DISEASE BY INHIBITION OF NITRIC OXIDE SYNTHASE1. Transplantation, 1997, 63, 94-100.	1.0	26
173	TACROLIMUS RESCUE THERAPY FOR RENAL ALLOGRAFT REJECTION-FIVE-YEAR EXPERIENCE1. Transplantation, 1997, 63, 223-228.	1.0	108
174	WEANING OF IMMUNOSUPPRESSION IN LIVER TRANSPLANT RECIPIENTS12. Transplantation, 1997, 63, 243-249.	1.0	383
175	EFFECT IN SUPRALETHALLY IRRADIATED RATS OF GRANULOCYTE COLONY-STIMULATING FACTOR AND LISOFYLLINE ON HEMATOPOIETIC RECONSTITUTION BY SYNGENEIC BONE MARROW OR WHOLE ORGAN PASSENGER LEUKOCYTES1. Transplantation, 1997, 63, 1840-1843.	1.0	13
176	CENTRAL VENULITIS IN THE ALLOGRAFT LIVER. Transplantation, 1997, 64, 252-257.	1.0	59
177	CLINICAL SIGNIFICANCE OF RENAL ALLOGRAFT BIOPSIES WITH ???BORDERLINE CHANGES,??? AS DEFINED IN THE BANFF SCHEMA1. Transplantation, 1997, 64, 992-995.	1.0	67
178	Adenovirus Hepatitis In The Adult Allograft Liver1. Transplantation, 1997, 64, 1483-1485.	1.0	42
179	Prevention of Transplant Rejection. BioDrugs, 1996, 6, 89-96.	0.7	0
180	Indefinite Survival of Rat Islet Allografts following Infusion of Donor Bone Marrow without Cytoablation. Cell Transplantation, 1996, 5, 53-55.	2.5	26

#	Article	IF	CITATIONS
181	The Two-Way Paradigm of Transplantation Immunology. Clinical Immunology and Immunopathology, 1996, 80, S46-S51.	2.0	23
182	A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: Intermediate-term results. Journal of Thoracic and Cardiovascular Surgery, 1996, 111, 764-772.	0.8	149
183	Liver transplants contribute to their own success. Nature Medicine, 1996, 2, 163-165.	30.7	62
184	MULTILINEAGE HEMATOPOIETIC RECONSTITUTION OF SUPRALETHALLY IRRADIATED RATS BY SYNGENEIC WHOLE ORGAN TRANSPLANTATION. Transplantation, 1996, 61, 1-4.	1.0	104
185	LACK OF SUSCEPTIBILITY OF BABOONS TO INFECTION WITH HEPATITIS B VIRUS. Transplantation, 1996, 61, 350,351.	1.0	33
186	TACROLIMUS PRETREATMENT ATTENUATES PREEXISTING XENOSPECIFIC IMMUNITY AND ABROGATES HYPERACUTE REJECTION IN A PRESENSITIZED HAMSTER TO RAT LIVER TRANSPLANT MODEL1. Transplantation, 1996, 61, 1730-1735.	1.0	7
187	EFFECT OF ANTICOMPLEMENT AGENT K76 COOH ON HAMSTER-TO-RAT AND GUINEA PIG-TO-RAT HEART XENOTRANSPLANTATION1. Transplantation, 1996, 62, 681-688.	1.0	19
188	Kidney/Bone Marrow Transplantation. Dialysis and Transplantation, 1996, 25, 282-287.	0.2	2
189	Immunopathology of cardiac transplant rejection. Current Opinion in Cardiology, 1995, 10, 193-206.	1.8	54
190	COMBINED SIMULTANEOUS KIDNEY/BONE MARROW TRANSPLANTATION1. Transplantation, 1995, 60, 1421-1425.	1.0	48
191	Immunoglobulin g lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology, 1995, 21, 1345-1352.	7.3	56
192	Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells, 1995, 13, 622-639.	3.2	182
193	Perioperative donor bone marrow infusion augments chimerism in heart and lung transplant recipients. Annals of Thoracic Surgery, 1995, 60, 1015-1020.	1.3	33
194	Reduction of FK-506 requirements by combination with polyethylene glycol superoxide dismutase in orthotopic rat liver transplantation. Journal of Allergy and Clinical Immunology, 1995, 95, 1276-1281.	2.9	3
195	The Bidirectional Paradigm of Transplant Immunology. Annals of the New York Academy of Sciences, 1995, 770, 165-176.	3.8	1
196	Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance*1. Hepatology, 1995, 21, 1345-1352.	7.3	5
197	Weaning Of Immunosuppression In Long-Term Liver Transplant Recipients. Transplantation, 1995, 59, 212-217.	1.0	12
198	Abdominal Multivisceral Transplantation. Transplantation, 1995, 59, 234-239.	1.0	9

#	Article	IF	CITATIONS
199	A PROSPECTIVE RANDOMIZED TRIAL OF FK506-BASED IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 485-490.	1.0	10
200	VARIABLE CHIMERISM, GRAFT-VERSUS-HOST DISEASE, AND TOLERANCE AFTER DIFFERENT KINDS OF CELL AND WHOLE ORGAN TRANSPLANTATION FROM LEWIS TO BROWN NORWAY RATS. Transplantation, 1995, 60, 158-170.	1.0	8
201	Cytokine Mrna Profiles In Mouse Orthotopic Liver Transplantation Graft Rejectionis Associasted With Augmented Th1 Function. Transplantation, 1995, 59, 274-281.	1.0	0
202	Combined Kidney/Bone Marrow Transplantationa Evidence Of Augmentation Of Chimerism. Transplantation, 1995, 59, 306-308.	1.0	0
203	Reversal of Graft-Versus-Host Disease with Infusion of Autologous Bone Marrow. Cell Transplantation, 1994, 3, 187-192.	2.5	18
204	The Potential Role of Cytokines in the Pathogenesis of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease. Leukemia and Lymphoma, 1994, 15, 383-387.	1.3	12
205	Murine liver allograft transplantation: Tolerance and donor cell chimerism. Hepatology, 1994, 19, 916-924.	7.3	465
206	Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology, 1994, 20, 376-382.	7.3	139
207	Mucosal recipient-type mononuclear repopulation and low-grade chronic rejection occur simultaneously in indefinitely surviving recipients of small bowel allografts. Transplant International, 1994, 7, 71-78.	1.6	8
208	Clinical xenotransplantation. Xenotransplantation, 1994, 1, 3-7.	2.8	12
209	Interferon-Î <sup>3</sup> Induced Expression of MHC Antigens Facilitates Identification of Donor Cells in Chimeric Transplant Recipients. Cell Transplantation, 1994, 3, 345-348.	2.5	3
210	Recurrent and de novo Giant Cell Hepatitis After Orthotopic Liver Transplantation. American Journal of Surgical Pathology, 1994, 18, 804-813.	3.7	78
211	SMALL INTESTINAL TRANSPLANTATION IN HUMANS WITH OR WITHOUT THE COLON1,2. Transplantation, 1994, 57, 840-847.	1.0	120
212	DONOR SPECIES COMPLEMENT AFTER LIVER XENOTRANSPLANTATION. Transplantation, 1994, 57, 918-922.	1.0	36
213	Mucosal recipient-type mononuclear repopulation and low-grade chronic rejection occur simultaneously in indefinitely surviving recipients of small bowel allografts. Transplant International, 1994, 7, 71-78.	1.6	6
214	Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology, 1994, 20, 376-382.	7.3	9
215	EVALUATION OF SEQUENTIAL SERUM INTERLEUKIN-6 LEVELS IN LIVER ALLOGRAFT RECIPIENTS. Transplantation, 1994, 57, 1037-1041.	1.0	3
216	SPLIT TOLERANCE INDUCED BY ORTHOTOPIC LIVER TRANSPLANTATION IN MICE1. Transplantation, 1994, 58, 1-7.	1.0	3

#	Article	IF	CITATIONS
217	Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology, 1993, 17, 1127-1152.	7.3	704
218	Hepatitis viral markers in patients undergoing primary liver transplants. Digestive Diseases and Sciences, 1993, 38, 457-461.	2.3	2
219	Intestinal transplantation in children under FK 506 immunosuppression. Journal of Pediatric Surgery, 1993, 28, 1040-1043.	1.6	33
220	Frequency and severity of HCV infection following orthotopic liver transplantation. Journal of Hepatology, 1993, 18, 279-283.	3.7	23
221	Allograft and Xenograft Acceptance under FK-506 and Other Immunosuppressant Treatment. Annals of the New York Academy of Sciences, 1993, 685, 46-51.	3.8	13
222	Chimerism after Liver Transplantation for Type IV Glycogen Storage Disease and Type 1 Gaucher's Disease. New England Journal of Medicine, 1993, 328, 745-749.	27.0	258
223	DENDRITIC CELL REPLACEMENT IN LONG-SURVIVING LIVER AND CARDIAC XENOGRAFTS. Transplantation, 1993, 56, 482-483.	1.0	20
224	HAMSTER-TO-RAT HEART AND LIVER XENOTRANSPLANTATION WITH FK506 PLUS ANTIPROLIFERATIVE DRUGS. Transplantation, 1993, 55, 701-708.	1.0	153
225	THE INFLUENCE OF HLA MATCHING ON CYTOMEGALOVIRUS HEPATITIS AND CHRONIC REJECTION AFTER LIVER TRANSPLANTATION. Transplantation, 1993, 55, 1067-1070.	1.0	97
226	GRAFT-VERSUS-HOST DISEASE AFTER BROWN NORWAY-TO-LEWIS AND LEWIS-TO-BROWN NORWAY RAT INTESTINAL TRANSPLANTATION UNDER FK506. Transplantation, 1993, 55, 1-7.	1.0	92
227	CHIMERISM AND DONOR-SPECIFIC NONREACTIVITY 27 TO 29 YEARS AFTER KIDNEY ALLOTRANSPLANTATION. Transplantation, 1993, 55, 1272-1276.	1.0	342
228	Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology, 1993, 17, 1127-1152.	7.3	40
229	HLA matching and the point system. Clinical Transplantation, 1993, 7, 353-356.	1.6	6
230	Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative Disease. New England Journal of Medicine, 1992, 327, 1710-1714.	27.0	202
231	Detection of Intrahepatic Human Islets Following Combined Liver-Islet Allotransplantation. Pancreas, 1992, 7, 507-509.	1.1	10
232	EVIDENCE THAT INDEFINITE SURVIVAL OF SMALL BOWEL ALLOGRAFTS ACHIEVED BY A BRIEF COURSE OF CYCLOSPORINE OR FK506 IS NOT DUE TO SYSTEMIC HYPORESPONSIVENESS. Transplantation, 1992, 54, 505-510.	1.0	17
233	CADAVERIC SMALL BOWEL AND SMALL BOWEL-LIVER TRANSPLANTATION IN HUMANS 1,2. Transplantation, 1992, 53, 369-375.	1.0	171
234	HUMAN ISLET ISOLATION AND ALLOTRANSPLANTATION IN 22 CONSECUTIVE CASES 1, 2. Transplantation, 1992, 53, 407-414.	1.0	227

#	Article	IF	CITATIONS
235	Ischemic Cholangitis. Mayo Clinic Proceedings, 1992, 67, 601-602.	3.0	13
236	Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Digestive Diseases and Sciences, 1992, 37, 1606-1611.	2.3	86
237	A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology, 1992, 16, 671-681.	7.3	129
238	Preformed lymphocytotoxic antibodies: The effects of class, titer and specificity on liver vs. heart allografts. Hepatology, 1992, 16, 1415-1422.	7.3	34
239	Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. International Journal of Cancer, 1992, 52, 252-260.	5.1	82
240	PREVENTION OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION IN RATS USING FK506. Transplantation, 1991, 52, 590-593.	1.0	48
241	Hepatic Resection Versus Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 1991, 214, 221-229.	4.2	614
242	Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology, 1991, 13, 619-626.	7.3	355
243	INHIBITION OF FREE RADICAL GENERATION AND IMPROVED SURVIVAL BY PROTECTION OF THE HEPATIC MICROVASCULAR ENDOTHELIUM BY TARGETED ERYTHROCYTES IN ORTHOTOPIC RAT LIVER TRANSPLANTATION. Transplantation, 1990, 49, 1055-1059.	1.0	33
244	Liver, Kidney, and Thoracic Organ Transplantation Under FK 506. Annals of Surgery, 1990, 212, 295-307.	4.2	261
245	Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes and Cancer, 1990, 2, 300-310.	2.8	53
246	Liver Transplantation. New England Journal of Medicine, 1989, 321, 1014-1022.	27.0	567
247	PRIMARY NONFUNCTION OF HEPATIC ALLOGRAFTS WITH PREEXISTING FATTY INFILTRATION1. Transplantation, 1989, 47, 903-904.	1.0	327
248	Abdominal Organ Cluster Transplantation for the Treatment of Upper Abdominal Malignancies. Annals of Surgery, 1989, 210, 374-386.	4.2	250
249	Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clinical Transplantation, 1989, 3, 37-45.	1.6	73
250	Pathologic analysis of liver transplantation for primary biliary cirrhosis. Hepatology, 1988, 8, 939-947.	7.3	77
251	TRANSMISSION OF FATAL HERPES SIMPLEX INFECTION THROUGH RENAL TRANSPLANTATION. Transplantation, 1988, 45, 653-655.	1.0	33
252	Primary carcinoma of stensen's duct: Recognition and management with literature review. Journal of Surgical Oncology, 1984, 27, 1-7.	1.7	18

IF

CITATIONS

## # ARTICLE

Histopathology of Intestinal Transplantation. , 0, , 322-330.